<DOC>
	<DOC>NCT01140529</DOC>
	<brief_summary>Primary hypothesis: Dexmedetomidine is equal or superior to haloperidol and placebo in the treatment of psychomotor confusion in patients who are recovering from heart surgery. Study design: Multi-centre, prospective, randomised, placebo-controlled double-blind study of dexmedetomidine vs. haloperidol for treatment of psychomotor confusion after cardiac surgery. Data will be analyzed in two steps: The primary comparison is between placebo and dexmedetomidine. If the effect of dexmedetomidine is significant, a secondary comparison between dexmedetomidine and haloperidol will follow.</brief_summary>
	<brief_title>Dexmedetomidine for the Treatment of Delirium After Heart Surgery</brief_title>
	<detailed_description />
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Confusion</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>Age &gt; 65 years Clinical need for treatment of psychomotor confusion unresponsive to standard analgesic medication (RASS +2 to +3) Heart surgery and extracorporeal circulation (ECC) within 7 days Written informed consent obtained before surgery Mentally competent at the time of written informed consent Ongoing neuroleptic, propofol and α2 agonist medication Intubated patient Uncompensated acute circulatory failure at time of randomisation (severe hypotension with mean arterial pressure &lt; 55 mmHg despite volume, vasopressors and IABP) Severe bradycardia without pacemaker backup (heart rate &lt; 50 beats/min) AVconduction block IIIII (without pacemaker backup) Severe hepatic impairment (Serum bilirubin &gt; 101 µmol/l) Lithium therapy</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Dexmedetomidine</keyword>
</DOC>